Barrett's Esophagus
Tools accurately identify risk for neoplastic BE vs frequency, duration of GERD
EsoGuard DNA test receives breakthrough designation
AI bests non-expert endoscopists in Barrett’s neoplasia detection
WATS brush effective for upper GI biopsies
Endoscopic submucosal dissection lowers recurrence rates in Barrett’s early neoplasia
ASGE releases updated screening, surveillance guidelines for BE
5 recent highlights involving the esophagus
Barrett’s with indefinite for dysplasia carries risk for progression
Patients with Barrett’s Esophagus with indefinite for dysplasia are at similar risk for malignant progression and should be screened like patients with low-grade dysplasia, according to results of a meta-analysis published in Gastrointestinal Endoscopy. “Currently, there are no reliable estimates for progression risk to [high-grade dysplasia/esophageal adenocarcinoma (HGD/EAC)] in patients with [Barrett’s esophagus with indefinite for dysplasia (BE-IND)],” Prasad G. Iyer, MD, MSc, from the division of gastroenterology and hepatology at Mayo Clinic in Rochester, Minnesota, and colleagues wrote. “Hence, management strategies for BE-IND are unclear and endoscopy is not routinely recommended.”